Seneca Therapeutics

Seneca Therapeutics' mission is to develop a first-class oncolytic immunotherapy to effectively treat all types of cancer patients.Seneca Therapeutics is developing the non-pathogenic Seneca Valley Virus isolate 001 (SVV-001) as a targeted immunotherapy that selectively kills cancer cells expressing the SVV-001 receptor TEM-8 and transforms the tumor microenvironment from cold to hot. SVV-001 is expected to synergize with immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance and cure more cancer patients.